REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 159 filers reported holding REATA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.74 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $8,184,000 | -51.6% | 56,698 | -31.5% | 1.08% | -36.5% |
| Q4 2019 | $16,921,000 | +160.5% | 82,773 | +2.3% | 1.69% | +158.7% |
| Q3 2019 | $6,496,000 | -12.3% | 80,908 | +3.1% | 0.65% | -14.3% |
| Q2 2019 | $7,403,000 | +9.4% | 78,458 | +1.1% | 0.76% | +9.6% |
| Q1 2019 | $6,765,000 | +65.2% | 77,578 | +6.3% | 0.70% | -3.7% |
| Q4 2018 | $4,094,000 | -28.9% | 72,968 | +3.7% | 0.72% | -19.2% |
| Q3 2018 | $5,755,000 | +135.9% | 70,388 | +0.9% | 0.90% | +116.7% |
| Q2 2018 | $2,440,000 | +70.5% | 69,788 | 0.0% | 0.41% | +67.2% |
| Q1 2018 | $1,431,000 | -27.6% | 69,788 | 0.0% | 0.25% | -26.9% |
| Q4 2017 | $1,976,000 | -8.9% | 69,788 | 0.0% | 0.34% | -13.6% |
| Q3 2017 | $2,170,000 | -1.7% | 69,788 | 0.0% | 0.39% | -2.2% |
| Q2 2017 | $2,208,000 | +39.7% | 69,788 | 0.0% | 0.40% | +39.9% |
| Q1 2017 | $1,581,000 | +54.1% | 69,788 | +48.5% | 0.29% | +48.2% |
| Q4 2016 | $1,026,000 | -17.2% | 47,000 | 0.0% | 0.19% | -18.6% |
| Q3 2016 | $1,239,000 | – | 47,000 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
| Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
| Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
| MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
| Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
| Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
| Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
| AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |